NCT01436487已完成2 期
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Healios K.K.
- 入组人数
- 134
- 试验地点
- 64
- 主要终点
- frequency of dose limiting adverse events
研究概览
简要总结
A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 83 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects between 18 and 83 years of age (inclusive)
- •Clinical diagnosis of cortical cerebral ischemic stroke
- •Occurrence of a moderate to moderately severe stroke
排除标准
- •Presence of a lacunar or a brainstem infarct
- •Reduced level of consciousness
- •Major neurological event such as stroke or clinically significant head trauma within 6 months of study
结局指标
主要结局
frequency of dose limiting adverse events
时间窗: 7 days
Stroke recovery based on global test analysis including modified Rankin Scale (mRS), NIHSS, and Barthel Index (BI)
时间窗: 90 days
次要结局
- proportion of subjects with a mRS score of less than or equal to 2(90 days)
- change in functional outcome throughout range of mRS scores(90 days)
- changes in outcome measures (mRS, NIHSS, BI) over time(365 days)
- proportion of subjects with an excellent functional outcome(90 days)
- frequency of adverse events(365 days)
- change in vital signs(365 days)
- change in safety labs(365 days)
- frequency of secondary infections(365 days)
研究者
研究点 (64)
Loading locations...
相似试验
已完成
1 期
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial InfarctionMyocardial InfarctionNCT00114452Mesoblast, Inc.60
已完成
1 期
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress SyndromeAcute Respiratory Distress SyndromeNCT02611609Healios K.K.36
招募中
1 期
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.Retinal DiseaseGeographic AtrophyEye DiseasesMacular DegenerationAge-Related Macular DegenerationNCT06394232Eyestem Research Pvt. Ltd.54
已完成
1 期
Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.Crohn's DiseaseAnal FistulaNCT01372969Tigenix S.A.U.24
已完成
1 期
Mesenchymal Stem Cells in Critical Limb IschemiaCritical Limb IschemiaNCT00883870Stempeutics Research Pvt Ltd20